Hair Loss Treatments - The Belgravia Centre

Hair Loss In Men

The pages within this menu have been carefully chosen to provide you with everything that you might be looking for related to men's hair loss. Please browse through the links provided for useful information on everything related to your problem.

Female Hair Loss Conditions

The Belgravia Centre is the UK's leading hair loss clinic for a reason! Find out about the clinics and why our medical facilities and hair loss products set us aside from the rest, and meet our team of more than 70 members of staff.

The Belgravia Centre

Complete Belgravia's online consultation if you are unable to visit one of our London clinics. The questionnaire should take no more than 10 minutes to complete and will provide our hair loss specialists with all the information required to recommend an effective course of home-use treatment. For those who live in or around London, we always recommend a clinical consultation.

Book a Consultation

Browse by Category

A new study has been set up in New York to see if people whose hair loss has been caused by the autoimmune disorder alopecia areata can benefit from subcutaneous injections of a specialist eczema medication.

The drug is named dupilumab and is quite well known to people who cannot use or have had no success with topical creams on their eczema – though it comes with a reported price tag of around $37,000 per year when sold under the brand name of Dupixent. The drug targets something called the IL-13 pathway, which has also been linked to alopecia areata. The theory is that using dupilumab on people with alopecia areata may reduce their shedding and encourage regrowth.

Vexing condition

Alopecia areata is a vexing condition that can strike without warning and usually leads to sudden patchy hair loss, although more extreme variations of the disorder (alopecia totalis and alopecia universalis) can lead to total baldness. Though alopecia areata treatment is possible using existing medications, the approach taken by specialist hair loss clinics is normally only effective when people present with the relatively mild, patchy form of the condition.

The New York trial is being overseen by the Icahn School of Medicine at Mount Sinai, and will involve a total of 54 people, half of whom will be given dupilumab, with the other half being given a placebo. Each set of volunteers will have 24 doses over the course of several months and any regrowth will be measured at 24 and 48 weeks. It will be a randomised double-blind trial and participants will only be accepted if their alopecia areata affects at least 30% of their scalp. Around a third of the volunteers are expected to also present with eczema/atopic dermatitis.

In the School’s description of the trial, submitted in its clinicaltrials.gov registration, it states: “Data shows that IL-13 is significantly upregulated in both AD (atopic dermatitis) and AA (alopecia areata) lesions compared to nonlesional skin. It is very important to associate the clinical responses with suppression of this cytokine and related molecules as well as other pathway cytokines in skin tissues. Both the whole genomic profiling and individual molecular and cellular markers are very important in order to understand how well anti-IL-13 will change/suppress AA-associated pathways and compare with those that will be suppressed in AD.”

Among the many exclusion criteria for would-be volunteers are use of any oral JAK inhibitors within 12 weeks before the start of the trial; the use of any systemic immunosuppressive medications; and also concurrent conditions that may also cause hairloss such as traction alopecia. The study is not expected to be completed until the end of 2023.

Existing treatments can be effective

The past few years have seen numerous stories about potential new treatment options for alopecia areata emerge, some of which are estimated to potentially become available as early as 2021. However, people with the relatively mild form of the disorder should note that existing treatments can be very effective.

In mild cases the hair should normally regrow naturally within up to 12 months, though if or when this hair growth will resume is unknown – something which can be extremely troubling for those affected. In these cases – when the rounded bald patches affect the scalp only – professional treatment can often lead to very satisfactory results, as can be seen in Belgravia’s alopecia areata success stories gallery.

The alopecia areata treatment provided via Belgravia’s specialists and pharmacies is for the scalp-only patchy hair loss version and involves recommended formulations of high strength minoxidil being applied directly to the affected areas to help encourage regrowth through opening the potassium channels. This drug is usually paired with further appropriatehair growth boosterstailored to the individual’s requirements and medical suitability.

The Belgravia Centre

The Belgravia Centreis the leader in hair loss treatment in the UK, with two clinics based in Central London. If you are worried about hair loss you can arrange a free consultation with a hair loss expert or complete our Online Consultation Form from anywhere in the UK or the rest of the world. View our Hair Loss Success Stories, which are the largest collection of such success stories in the world and demonstrate the levels of success that so many of Belgravia’s patients achieve. You can also phone 020 7730 6666 any time for our hair loss helpline or to arrange a free consultation.